Ordering under an unremarkable name and address is the whole method. It requires no cooperation from anybody and it produces the strongest evidence this index holds.
AX-2025-019844
Semaglutide · 10 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2506-M5731
FAILVERIFIED
- Report ID
- AX-2025-019844
- Compound
- Semaglutide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- Homopeptide — Hunan Aslsen Technology Co., Ltd.
- Batch / lot
- HOMO-2506-M5731
- Declared label claim
- 10mg
- Laboratory
- PeptideMeter
- Assay date
- 16 Aug 2025
- Submitted
- 04 Sep 2025
- Quarter
- 2025-Q3
- Submitter
- r.rasmussen
- Sample provenance
- Buyer-sourced
Section 1
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 28 min gradient, 214 nm | 98.02 | % area | ≥ 97.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.98 | % area | ≤ 3.0 | PASS |
| Largest single impurity | RP-HPLC — Met(O) sulfoxide (+16 Da) | 0.79 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 4111.0524 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 4111.2251 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +42.0 | ppm | ± 15 | FAIL |
| Total peptide content | by difference from the gravimetric mass balance | 82.62 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 80.98 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 11.26 | mg | 10 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 9.118 | mg | 10 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 91.2 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 6.19 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 10.67 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.52 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | membrane filtration, USP <71>, 14 d | No growth at 14 d | — | no growth | PASS |
| Appearance | visual, diffuse light, black and white background | White cake, partial shrinkage from vial wall | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 3.71 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 28 min gradient | 17.25 | min | 17.29 ± 0.45 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.12 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 56,929 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Aib8]-diastereomer | 0.76 | — | no index criterion | REPORTED |
Section 2
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Semaglutide — main peak | 17.25 | 4,764,076 | 98.02 | — |
| 2 | Met(O) sulfoxide (+16 Da) | 16.62 | 38,396 | 0.79 | +15.995 |
| 3 | tBu-protected residual (+56 Da) | 19.16 | 27,218 | 0.56 | +56.063 |
| 4 | C18 diacid mono-ester | 18.52 | 20,899 | 0.43 | +14.016 |
| 5 | [D-Aib8]-diastereomer | 17.03 | 6,318 | 0.13 | 0.000 |
| 6 | semaglutide dimer | 20.71 | 1,944 | 0.04 | +4111.052 |
| 7 | des-AEEA semaglutide (−145 Da) | 16.48 | 1,458 | 0.03 | -145.074 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Section 3
Mass spectrum and identity
Theoretical monoisotopic mass 4111.0524 Da, computed from C187H291N45O59. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 6+ | 686.1827 | 686.2115 | 0.0288 | 8.9 |
| 5+ | 823.2178 | 823.2523 | 0.0345 | 60.5 |
| 4+ | 1028.7704 | 1028.8136 | 0.0432 | 100.0 |
| 3+ | 1371.3581 | 1371.4156 | 0.0575 | 59.0 |
| 2+ | 2056.5335 | 2056.6198 | 0.0863 | 9.1 |
Section 4
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 6.19 |
| Counter-ion (TFA) | ion chromatography | 10.67 |
| Residual solvent + inorganic residue | estimated | 0.52 |
| Total peptide content | by difference | 82.62 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 98.08 | 98.02 | divergence +0.23 pp vs batch median |
| Total impurities (% area) | 1.92 | 1.98 | |
| Largest single impurity (% area) | 1.05 | 0.79 | |
| Water (%) | not stated | 6.19 | |
| Counter-ion (%) | 7.9 | 10.67 | |
| Peptide content (%w/w) | 88.0 | 82.62 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Section 5
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (−20 °C, 15 d) → laboratory (courier, dry ice, 6 d) → assay.
- Assay date
- 16 Aug 2025
- Submitted to the index
- 04 Sep 2025
- Laboratory
- PeptideMeter, Tallinn, Estonia
- Method basis
- 28 min gradient · high-resolution MS
- Verification status
- VERIFIED
Section 6
Annotations 5
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Met(O) sulfoxide (+16 Da) at 0.79 % elutes close enough to the main peak that drop-line and valley-to-valley will not agree. The index prints the resolution figure and applies no criterion to it — how close the nearest impurity sits is a property of the compound and the gradient, not of the system. What matters is that the convention used is stated.
Resolution to the nearest named impurity is reported on this record with no verdict attached, which is the correct handling. A threshold on that figure would penalise compounds for their own impurity profiles.
Valley height relative to the smaller peak is the practical criterion an operator uses, and it is not on the report. Resolution is a proxy for it and an imperfect one on asymmetric pairs.
Agreed, and nothing further from me.
Section 7
Related records
Same batch — lot HOMO-2506-M5731 n=15
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-019835 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 97.60 | 5.68 | 92.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019836 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 98.06 | 6.25 | 89.0 | Buyer-sourced | 2 | MARGINAL |
| AX-2025-019837 | HOMO-2506-M5731 | Medutest | 2025-Q3 | 97.98 | 5.88 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019838 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 97.24 | 6.37 | 95.9 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019839 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 98.10 | 6.45 | 95.7 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019840 | HOMO-2506-M5731 | PeptideMeter | 2025-Q3 | 97.51 | 5.91 | 88.7 | Buyer-sourced | 2 | MARGINAL |
| AX-2025-019841 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 97.93 | 6.02 | 91.4 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019842 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 97.60 | 6.12 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019843 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 97.85 | 5.54 | 104.3 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019845 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 97.36 | 6.24 | 94.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019846 | HOMO-2506-M5731 | Nordanalyt | 2025-Q3 | 97.48 | 6.23 | 89.5 | Buyer-sourced | 2 | MARGINAL |
| AX-2025-019847 | HOMO-2506-M5731 | VendorInvestigate | 2025-Q3 | 97.36 | 6.04 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019848 | HOMO-2506-M5731 | PeptideMeter | 2025-Q3 | 97.96 | 5.88 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019849 | HOMO-2506-M5731 | Janoshik | 2025-Q3 | 98.01 | 6.54 | — | Buyer-sourced | 1 | MARGINAL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043376 | WXT | WXT-2604-C3248 | Janoshik | 2026-Q3 | 97.08 | 4.22 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042424 | Homopeptide | HOMO-2604-X3806 | PeptideMeter | 2026-Q3 | 98.85 | 4.87 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041643 | FGP | FGP-2602-M8547 | Janoshik | 2026-Q3 | 99.31 | 2.79 | 100.7 | Buyer-sourced | 0 | PASS |
| AX-2026-041334 | WWB | WWB-2606-N3192 | Janoshik | 2026-Q3 | 98.93 | 4.62 | 99.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042002 | AMB | AMB-2607-N6274 | VendorInvestigate | 2026-Q3 | 98.23 | 6.37 | 97.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041337 | WWB | WWB-2606-N3192 | Nordanalyt | 2026-Q3 | 99.52 | 3.92 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042595 | HJ | HJ-2608-C7002 | Janoshik | 2026-Q3 | 99.50 | 3.55 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042217 | TFC | TFC-2604-X9037 | PeptideMeter | 2026-Q3 | 98.95 | 4.61 | 96.9 | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042437 | Retatrutide | HOMO-2605-V4718 | Nordanalyt | 2026-Q3 | 98.68 | 3.67 | 102.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042424 | Semaglutide | HOMO-2604-X3806 | PeptideMeter | 2026-Q3 | 98.85 | 4.87 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-042503 | IGF-1 LR3 | HOMO-2607-P5131 | Janoshik | 2026-Q3 | 99.36 | 5.99 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042492 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Medutest | 2026-Q3 | 99.93 | 2.40 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042491 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Kestrel | 2026-Q3 | 99.93 | 3.24 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042473 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.01 | 5.00 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042441 | Retatrutide | HOMO-2605-V4718 | Medutest | 2026-Q3 | 98.93 | 4.22 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042474 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.18 | 5.44 | — | Buyer-sourced | 0 | PASS |